PTEN mutations have never been associated with PCC in humans, but PTEN is an important key player in regulating the AKT and mammalian target of rapamycin (mTOR) pathways, which are altered in human PCC. This evidence concerns the gene AKT1 and adrenal gland pheochromocytoma.